Last10K.com

Mesoblast Ltd (MESO) SEC Filing 6-K Foreign Issuer report for the period ending Thursday, February 21, 2019

Mesoblast Ltd

CIK: 1345099 Ticker: MESO

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of February 2019

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(
Jurisdiction of incorporation or organization)

 

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

 


INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On February 19, 2019, Mesoblast Limited filed with the Australian Securities Exchange new release announcements, which are attached hereto as Exhibit 99.1 and Exhibit 99.2, and are incorporated herein by reference.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

 

 

 

 

 

 

 

 

Mesoblast Limited

 

 

 

 

 

 

/s/ Charlie Harrison

 

 

 

 

 

 

 

 

 

Charlie Harrison

 

 

 

 

Company Secretary

 

 

 

Dated: February 21, 2019


INDEX TO EXHIBITS

 

 

 

Item

 

 

 

 

 

99.1

 

Press Release of Mesoblast Ltd, dated February 19, 2019.

99.2

 

Press Release of Mesoblast Ltd, dated February 19, 2019.

 

 

 

 

 

 

 

 

 

View differences made from one to another to evaluate Mesoblast Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mesoblast Ltd.

Continue

Assess how Mesoblast Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Mesoblast Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Mesoblast Ltd provided additional information to their SEC Filing as exhibits

Ticker: MESO
CIK: 1345099
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001564590-19-003733
Submitted to the SEC: Thu Feb 21 2019 5:41:42 PM EST
Accepted by the SEC: Fri Feb 22 2019
Period: Thursday, February 21, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/meso/0001564590-19-003733.htm